Abstract
Objective: Previous studies suggest that cytologic analysis of cells obtained by lavage of the pleural surfaces at the time of resection of non-small cell lung cancer can identify patients at risk for recurrence. Because telomerase gene expression has been associated with worse outcome in non-small cell lung cancer, we hypothesized that identification of cells obtained from pleural lavage that express telomerase would identify patients at risk for recurrent disease. Methods: Patients with presumed non-small cell lung cancer underwent thoracotomy with curative intent. Cells obtained by lavage of the pleural surfaces were analyzed for telomerase catalytic subunit human telomerase reverse transcriptase mRNA expression using reverse transcriptase polymerase chain reaction. Results: A total of 194 patients with stage I/II non-small cell lung cancer had adequate samples, and median follow-up was 60 months (17-91 months). By using Cox models, no statistical differences were found between human telomerase reverse transcriptase-negative and positive patients in disease-free survival (hazard ratio, 1.28; 95% confidence interval, 0.85-1.94; log-rank test, P =.2349) or overall survival (hazard ratio, 1.13; 95% confidence interval, 0.72-1.79; log-rank test, P =.5912) Conclusions: Detection of human telomerase reverse transcriptase in cells obtained from pleural lavage of patients with stage I/II non-small cell lung cancer does not identify patients at risk for recurrent disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 206-211 |
| Number of pages | 6 |
| Journal | Journal of Thoracic and Cardiovascular Surgery |
| Volume | 146 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jul 2013 |
Bibliographical note
Funding Information:University of Maryland Greenebaum Cancer Center, Baltimore, Md, Martin Edelman, MD; supported by CA31983.
Funding Information:
Dana-Farber Cancer Institute, Boston, Mass, Harold J Burstein, MD, PhD; supported by CA32291.
Funding Information:
University of Missouri/Ellis Fischel Cancer Center, Columbia, Mo, Michael C. Perry, MD; supported by CA12046.
Funding Information:
Funding: The research for CALGB 159902 was supported in part by National Cancer Institute R21 CA81489-01 . It was also supported, in part, by grants from the National Cancer Institute ( CA31946 ) to the Cancer and Leukemia Group B (Monica M. Bertagnolli, MD, Chair) and to the CALGB Statistical Center (Daniel J. Sargent, PhD, CA33601). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.
Funding Information:
Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, NY; supported by CA21060.
Funding Information:
Medical University of South Carolina, Charleston, SC, Mark Green, MD; supported by CA03927.
Funding Information:
CALGB Statistical Center, Duke University Medical Center, Durham, NC; supported by CA33601.
Funding Information:
Department of Surgery, Duke University Medical Center, Durham, NC; supported by CA47577.
Funding Information:
Southeast Cancer Control Consortium Inc. CCOP, Goldsboro, NC, James N. Atkins, MD; supported by CA45808.
